Novo Nordisk
Executive Summary
Nasal insulin product will not be introduced "in this decade" after clinical trials with a revised formulation failed to sufficiently lower blood glucose levels, Danish firm announces Dec. 16. Novo had previously anticipated a one to two-year delay while it attempted to improve the formulation ("The Pink Sheet" March 16, p. 17), but now expects further delays and possible termination of the project.